ACR Congress Review 2019
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
References<br />
Bergman M, Tanaka Y, Citera G, Bahlas S, Ali M, Meerwein S, Song Y, Strand V. Upadacitinib treatment and the routine assessment of<br />
patient index data 3 (RAPID3) among patients with rheumatoid arthritis. Arthritis Rheumatol. <strong>2019</strong>; 71 (suppl 10):A551.<br />
Bergman M, Tundia N, Camp H, Meerwein S, Schlacher C, Goldschmidt D, Song Y, Strand V. Effects of upadacitinib on patient-reported<br />
outcomes after 24 weeks in patients with active rheumatoid arthritis and an inadequate response to conventional synthetic or biologic<br />
disease-modifying anti-rheumatic drugs: results from SELECT-NEXT and SELECT-BEYOND phase 3 studies. Arthritis Rheumatol. <strong>2019</strong>;<br />
71 (suppl 10):A1352.<br />
Bessette L, Dougados M, Mysler E, Genovese M, Kinch C, Kwok K, Lukic T, Girard T, Landry P, van Vollenhoven R. Impact of tofacitinib<br />
on the individual components of the <strong>ACR</strong> composite score in patients with rheumatoid arthritis: a post hoc analysis of phase 3 trials.<br />
Arthritis Rheumatol. <strong>2019</strong>; 71 (suppl 10):A1348.<br />
Buch M, Wells A, Rubbert-Roth A, Jain M, Schlacher C, Camp H, Li Y, Song Y, Nash P. A comparative analysis of upadacitinib<br />
monotherapy and upadacitinib combination therapy for the treatment of rheumatoid arthritis from two phase 3 trials. Arthritis Rheumatol.<br />
<strong>2019</strong>; 71 (suppl 10):A511.<br />
Burmester G, Van den Bosch F, Bessette L, Kivitz A, Li Y, Friedman A, Pangan A, Camp H, Kremer J. Long-term safety and efficacy of<br />
upadacitinib in patients with rheumatoid arthritis and an inadequate response to csDMARDs: Results at 60 weeks. Arthritis Rheumatol.<br />
<strong>2019</strong>; 71 (suppl 10):A538.<br />
Charles-Schoeman C, Sornasse T, Sokolove J. Treatment with upadacitinib is associated with improvements in reverse cholesterol<br />
transport in patients with rheumatoid arthritis: correlation with changes in inflammation and HDL levels. Arthritis Rheumatol. <strong>2019</strong>; 71 (suppl<br />
10):A510.<br />
Choy E, McInnes I, Cush J, Aelion J, Zhang Y, Khan N, Liu J, Camp H, Meerwein S, Rigby W, Cohen A. MACE and VTE across multiple<br />
upadacitinib studies in rheumatoid arthritis: integrated analysis from the SELECT phase 3 clinical program. Arthritis Rheumatol. <strong>2019</strong>; 71<br />
(suppl 10):A846.<br />
Citera G, Jain R, Irazoque F, Guzman R, Madariaga H, Gruben D, Wang L, Stockert L, Hsu M, Santana K, Ebrahim A, Ponce de Leon D.<br />
Tofacitinib in patients with rheumatoid arthritis and indicative of depression and/or anxiety: a post hoc analysis of phase 3 and phase 3b/4<br />
clinical trials. Arthritis Rheumatol. <strong>2019</strong>; 71 (suppl 10):A1444.<br />
Coates L, Mease P, Gladman D, Van den Bosch F, Rychlewska-Hanczewska A, Tasset C, Meuleners L, Trivedi M, Gao J, Besuyen R,<br />
Helliwell P. Long-term safety of filgotinib in patients with psoriatic arthritis, week 52 safety data from a phase 2 open-label extension study.<br />
Arthritis Rheumatol. <strong>2019</strong>; 71 (suppl 10):A1534.<br />
Cohen S, Pope J, Haraoui B, Mysler E, Diehl A, Lukic T, Liu S, Stockert L, Menon S, Keystone E. Efficacy and safety of tofacitinib modifiedrelease<br />
11 mg once daily + MTX in RA patients with an inadequate response to MTX: open-label phase results from a global phase 3b/4<br />
MTX withdrawal study. Arthritis Rheumatol. <strong>2019</strong>; 71 (suppl 10):A1412.<br />
Cohen S, Tuckwell K, Kunder R, Katsumoto T, Zhao R, Berman A, Damjanov N, Fedkov D, Jeka S, Genovese M. Efficacy and safety of<br />
fenebrutinib, a BTK inhibitor, compared to placebo in rheumatoid arthritis patients with active disease despite TNF inhibitor treatment:<br />
Randomised, Double Blind, Phase 2 Study. Arthritis Rheumatol. <strong>2019</strong>; 71 (suppl 10):A929.<br />
Cohen S, van Vollenhoven R, Winthrop K, Zerbini C, Tanaka Y, Bessette L, Zhang Y, Khan N, Hendrickson B, Enejosa J, Burmester G.<br />
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase 3 clinical program. Arthritis Rheumatol.<br />
<strong>2019</strong>; 71 (suppl 10):A509.<br />
Combe B, Kivitz A, Tanaka Y, van der Heijde D, Matzkies F, Bartok B, Ye L, Guo Y, Tasset C, Sundy J, Mozaffarian N, Landewé R, Bae S,<br />
Keystone E, Nash P. Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate:<br />
FINCH1 primary outcome results. Arthritis Rheumatol. <strong>2019</strong>; 71 (suppl 10):A506.<br />
Croiteru A, Lidar M, Reitblat T, Zisman D, Balbir-Gurman A, Meshiach T, Almog R, Elkayam O. Real life retention of tofacitinib in patients<br />
with rheumatoid arthritis. Arthritis Rheumatol. <strong>2019</strong>; 71 (suppl 10):A1400.<br />
Danto S, Shojaee N, Singh R, Manukyan Z, Mancuso J, Peeva E, Vincent M, Beebe J. Efficacy and safety of the selective interleukin-1<br />
receptor associated kinase 4 inhibitor, PF-06650833, in patients with active rheumatoid arthritis and inadequate response to methotrexate.<br />
Arthritis Rheumatol. <strong>2019</strong>; 71 (suppl 10):A2909.<br />
Di Paolo J, Downie B, Meng A, Mollova N, Yu Y, Han P. Evaluation of potential mechanisms underlying the safety observations of filgotinib<br />
in clinical studies in RA. Arthritis Rheumatol. <strong>2019</strong>; 71 (suppl 10):A59.<br />
Dougados M, van der Heijde D, Bingham C, Taylor P, Fallon L, Woolcott J, Brault Y, Wang L, Kessouri M. The effect of tofacitinib on<br />
residual pain in patients with psoriatic arthritis. Arthritis Rheumatol. <strong>2019</strong>; 71 (suppl 10):A1502.<br />
Fleischmann R, Bergman M, Tundia N, Song I, Suboticki J, Song Y, Strand V. Patient-reported outcomes of upadacitinib versus<br />
*Chairman’s Pick